HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery
HTS 靶向 HIV-1 蛋白酶自动处理以实现一流药物发现
基本信息
- 批准号:9919988
- 负责人:
- 金额:$ 80.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntiviral AgentsBindingBiochemicalBiologicalBiological AssayBiological SciencesCatalogsCatalytic DomainCellsChemicalsCollaborationsCollectionDrug DesignDrug resistanceEnzyme-Linked Immunosorbent AssayEnzymesFDA approvedFractionationGeneticGoalsHIVHIV-1HIV-1 proteaseInstitutesLeadLifeLongevityMediatingMedicalMichiganMicrobeMolecular ConformationMutationNatural ProductsPatientsPeptide HydrolasesPerformancePhenotypePredispositionProcessProductionProtease InhibitorProteolysisRNA-Directed DNA PolymeraseReactionReportingResistanceSagittariaStructureTechnologyTherapeuticTherapeutic AgentsTimeTreatment EfficacyUniversitiesViralVirionanalogantiretroviral therapyassay developmentbasecombatdrug discoveryfollow-uphigh throughput screeningimprovedinhibitor/antagonistinsightnovelnovel therapeutic interventionnovel therapeuticsoutcome forecastpol Gene Productsresistant strainresponsescreeningsmall moleculesmall molecule librariestherapeutic developmenttherapeutic targettherapy outcome
项目摘要
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery
Project Summary
This proposal is in response to PAR-17-438: Assay development and screening for discovery of chemical probes
or therapeutic agents (R01). The goal of this project is to carry out high-throughput screens and follow-up
characterizations to identify molecules inhibiting HIV-1 protease (PR) autoprocessing with modes of action
(MOAs) different from the currently available protease inhibitors (PIs). In the infected cell, HIV-1 PR is initially
synthesized as part of the Gag-Pol polyprotein precursor with its proteolysis activity tightly suppressed. During
late stage of virion production, the precursor self-catalyzes the cleavage reactions that lead to liberation of the
free mature PR in a temporospatially regulated fashion. The FDA-approved HIV-1 PIs primarily target the
catalytic site of the mature PR and they are significantly less effective at suppressing precursor-mediated
autoprocessing, suggesting that these two forms of HIV-1 PR are enzymatically different. Also, the emergence
of PI resistant strain in patients treated with PI-containing combination antiretroviral therapy (cART) is an ongoing
problem that diminishes treatment efficacy, which warrants the need for new therapeutics. This project seeks to
find novel autoprocessing inhibitors targeting the precursor at regions not recognized by the currently available
PIs. Towards this goal, we have established a cell-based functional assay that has faithfully recapitulated the
autoprocessing phenotypes observed with proviral constructs. This assay has also, for the first time, made it
possible to screen for autoprocessing inhibitors by HTS using AlphaLISA (amplified luminescent proximity
homogeneous assay ELISA) technology. Our pilot screens of ~26K small molecule compounds displayed
satisfactory performance with Z’ factors >0.45, S/N ratios >10, and hit rates <0.1% although no confirmed hit
was identified. Therefore, we plan to screen a collection of natural product extracts (40K extracts, 5-25
compounds per extract, totaling ~0.6 million chemicals) with a wild type and two PI resistant precursors in
collaboration with Dr. David Sherman at University of Michigan Life Sciences Institute (Aim 1). In parallel, we
will team up with Drs. Thomas Chung and Ian Pass at Sanford Burnham Prebys Medical Discovery Institute to
screen their ~350K small molecule library (Aim 2). These HTS campaigns will hopefully identify a handful
confirmed compounds that will be subjected to a battery of established secondary and tertiary assays (Aim 3) in
order to find novel autoprocessing inhibitors that are different from the current HIV-1 PIs in their MOA. This next
generation of therapeutic probes, when used in combination with the current PIs, will implement a new
therapeutic approach: targeting a vital enzyme (HIV-1 protease) at two distinct functional states (precursor and
mature PR) and at different regions (non-catalytic and catalytic sites) at the same time. Such a strategy is
expected to drastically increase difficulty (genetic barrier) for HIV-1 to evolve viable strains simultaneously
resistant to inhibitors from both classes to resist the resistance.
HTS靶向HIV-1蛋白酶自动加工,用于一流的药物发现
项目摘要
本提案是对PAR-17-438:用于发现化学探针的检测开发和筛选的响应
或治疗剂(R 01)。本项目的目标是进行高通量筛选和后续
鉴定抑制HIV-1蛋白酶(PR)自动加工的分子及其作用模式的表征
在一些实施方案中,本发明涉及与目前可用的蛋白酶抑制剂(PI)不同的MOA。在受感染的细胞中,HIV-1 PR最初是
作为Gag-Pol多聚蛋白前体的一部分合成,其蛋白水解活性受到严格抑制。期间
在病毒体产生的后期阶段,前体自催化裂解反应,导致病毒体的释放。
以时空调节的方式释放成熟PR。FDA批准的HIV-1 PI主要针对
在成熟PR的催化位点上,它们在抑制受体介导的
自动加工,这表明这两种形式的HIV-1 PR是不同的酶。此外,
在接受含PI的联合抗逆转录病毒治疗(cART)的患者中,PI耐药株的研究正在进行中。
降低治疗效果的问题,这保证了对新疗法的需要。本项目谋求
发现新的自动加工抑制剂,靶向目前可用的未识别的区域的前体
私家侦探为了实现这一目标,我们建立了一个基于细胞的功能测定,忠实地概括了
用前病毒构建体观察到的自动加工表型。这项试验也首次使
可以使用AlphaLISA(放大的发光邻近度)通过HTS筛选自动加工抑制剂
均相测定ELISA)技术。我们的~ 26 K小分子化合物的中试筛选显示
令人满意的性能,Z'因子>0.45,S/N比>10,命中率<0.1%,但未确认命中
被确认了因此,我们计划筛选一系列天然产物提取物(40 K提取物,5-25
化合物,总计约60万种化学物质),其中野生型和两种PI抗性前体在
与密歇根大学生命科学研究所的大卫谢尔曼博士合作(目标1)。同时,我们
将与Sanford Burnham Prebys医学发现研究所的托马斯钟博士和伊恩帕斯博士合作,
筛选其~ 350 K小分子文库(Aim 2)。这些HTS活动将有望确定少数
已确认的化合物将在以下研究中进行一系列已建立的二级和三级试验(目标3):
为了找到新的自加工抑制剂,是从目前的HIV-1 PI在其MOA不同。下一
新一代治疗探针与当前PI结合使用时,将实现新的
治疗方法:以两种不同功能状态(前体和
成熟的PR)和不同的区域(非催化和催化位点)。这样的策略
预计将大大增加HIV-1同时进化出可行菌株的难度(遗传障碍)
对来自两类的抑制剂具有抗性以抵抗抗性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHAOPING CHEN其他文献
CHAOPING CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHAOPING CHEN', 18)}}的其他基金
Assay Development and Validation for Precision Antiretroviral Therapy to Combat Drug Resistance
对抗耐药性的精准抗逆转录病毒疗法的测定开发和验证
- 批准号:
10882256 - 财政年份:2023
- 资助金额:
$ 80.4万 - 项目类别:
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery
HTS 靶向 HIV-1 蛋白酶自动处理以实现一流药物发现
- 批准号:
10553592 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别:
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery
HTS 靶向 HIV-1 蛋白酶自动处理以实现一流药物发现
- 批准号:
10318957 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别:
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery
HTS 靶向 HIV-1 蛋白酶自动处理以实现一流药物发现
- 批准号:
10077828 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别:
Assay Development for Identification of HIV-1 Protease Autoprocessing Specific Inhibitors
HIV-1 蛋白酶自动加工特异性抑制剂鉴定的检测方法开发
- 批准号:
9332334 - 财政年份:2016
- 资助金额:
$ 80.4万 - 项目类别:
Assay Optimization for Identification of Novel HIV-1 Protease Autoprocessing Inhi
新型 HIV-1 蛋白酶自动加工酶鉴定的测定优化
- 批准号:
8789526 - 财政年份:2014
- 资助金额:
$ 80.4万 - 项目类别:
Assay Optimization for Identification of Novel HIV-1 Protease Autoprocessing Inhi
新型 HIV-1 蛋白酶自动加工酶鉴定的测定优化
- 批准号:
8892994 - 财政年份:2014
- 资助金额:
$ 80.4万 - 项目类别:
Isolation and Characterization of Aptamers Targeted to Inhibit HIV Protease Matur
抑制 HIV 蛋白酶成熟的适体的分离和表征
- 批准号:
7756254 - 财政年份:2009
- 资助金额:
$ 80.4万 - 项目类别:
Isolation and Characterization of Aptamers Targeted to Inhibit HIV Protease Matur
抑制 HIV 蛋白酶成熟的适体的分离和表征
- 批准号:
7860304 - 财政年份:2009
- 资助金额:
$ 80.4万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 80.4万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 80.4万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 80.4万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 80.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 80.4万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 80.4万 - 项目类别: